Skip to main content
Displaying 1 - 12 of 24
Display:
12
24
48
Viral Hepatitis
1
GlaxoSmithKline: Nothing about me without me - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
6
Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022
View
Viral Hepatitis
6
AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022
View
Viral Hepatitis
6
AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022
View
Pagination
Current page
1
Page
2
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy